EPIK-B3: A phase III, randomised, double-blind (DB),...

Annals of Oncology 2020 / 09 Vol. 31

EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) + nab-paclitaxel (nab-PTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation

Sharma, P., Farooki, A., Fasching, P.A., Loi, S., Peterson, K., Prat, A., Tripathy, D., Xu, B., Yardley, D.A., Mills, D., Klauss, G., Wong, C., André, F.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
31
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2020.08.451
Date:
September, 2020
File:
PDF, 99 KB
2020
Conversion to is in progress
Conversion to is failed